How has community pharmacy responded to COVID-19?

Loading...

Taking too long?

Reload document

| Open in new tab

Investigating how community pharmacy has responded to COVID-19 pandemic to maintain patient safety

Study overview

Our study seeks to explore how community pharmacy is responding to the current pandemic whilst maintaining patient safety. We will be asking community pharmacists to share their experiences of how they have adapted practice to ensure patient safety through the early and later stages of the pandemic.

Purpose of the study

Community pharmacies have been central to the NHS response to the pandemic, and while some healthcare services may have had to adapt by providing limited or remote access to patients, they have remained open to maintain public access to pharmaceutical care. We would like to explore the experiences of community pharmacists during pre-lockdown, lockdown, and the period of relaxing lockdown, so that we can learn how patient safety was maintained, and how community pharmacy was and could be further supported, during this pandemic.

Your community pharmacies’ participation in this research will help inform the development of resilient practice in community pharmacy, to better prepare for future crises and further outbreaks of COVID-19.

Who we are

This study is led by researchers from the Universities of Bradford and Leeds as part of the National Institute for Health Research Yorkshire and Humber Patient Safety Translational Research Centre (PSTRC; please see our website). The PSTRC has an overarching aim to deliver research that makes healthcare safer. We are a partnership of multidisciplinary patient safety researchers, working closely with the NHS across all healthcare organisations.

Contact information

If you wish to know more about the study, please contact our team:

Mr George Peat, Senior Research Fellow: g.w.peat@bradford.ac.uk;

Dr Janice Olaniyan, Research Fellow: j.o.olaniyan@bradford.ac.uk;

Dr Liz Breen, Reader in Health Service Operations: l.breen@bradford.ac.uk; and Professor David Alldred, Professor of Medicines Use and Safety: d.p.alldred@leeds.ac.uk.

Ethical approval for this study was awarded by the Chair of the Biomedical, Natural, Physical and Health Sciences Research Ethics Panel at the University of Bradford 17/06/2020 (Ref: E817).